Skip to main content
Top
Published in: Diabetologia 1/2022

01-01-2022 | Macroalbuminuria | Article

Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes

Authors: Stefan Mutter, Erkka Valo, Viljami Aittomäki, Kristian Nybo, Lassi Raivonen, Lena M. Thorn, Carol Forsblom, Niina Sandholm, Peter Würtz, Per-Henrik Groop

Published in: Diabetologia | Issue 1/2022

Login to get access

Abstract

Aims/hypothesis

This prospective, observational study examines associations between 51 urinary metabolites and risk of progression of diabetic nephropathy in individuals with type 1 diabetes by employing an automated NMR metabolomics technique suitable for large-scale urine sample collections.

Methods

We collected 24-h urine samples for 2670 individuals with type 1 diabetes from the Finnish Diabetic Nephropathy study and measured metabolite concentrations by NMR. Individuals were followed up for 9.0 ± 5.0 years until their first sign of progression of diabetic nephropathy, end-stage kidney disease or study end. Cox regressions were performed on the entire study population (overall progression), on 1999 individuals with normoalbuminuria and 347 individuals with macroalbuminuria at baseline.

Results

Seven urinary metabolites were associated with overall progression after adjustment for baseline albuminuria and chronic kidney disease stage (p < 8 × 10−4): leucine (HR 1.47 [95% CI 1.30, 1.66] per 1-SD creatinine-scaled metabolite concentration), valine (1.38 [1.22, 1.56]), isoleucine (1.33 [1.18, 1.50]), pseudouridine (1.25 [1.11, 1.42]), threonine (1.27 [1.11, 1.46]) and citrate (0.84 [0.75, 0.93]). 2-Hydroxyisobutyrate was associated with overall progression (1.30 [1.16, 1.45]) and also progression from normoalbuminuria (1.56 [1.25, 1.95]). Six amino acids and pyroglutamate were associated with progression from macroalbuminuria.

Conclusions/interpretation

Branched-chain amino acids and other urinary metabolites were associated with the progression of diabetic nephropathy on top of baseline albuminuria and chronic kidney disease. We found differences in associations for overall progression and progression from normo- and macroalbuminuria. These novel discoveries illustrate the utility of analysing urinary metabolites in entire population cohorts.

Graphical abstract

Appendix
Available only for authorised users
Literature
11.
go back to reference Lithovius R, Harjutsalo V, Mutter S, Gordin D, Forsblom C, Groop P-H (2020) Resistant hypertension and risk of adverse events in individuals with type 1 diabetes: a Nationwide prospective study. Diabetes Care. 43(8):1885–1892. https://doi.org/10.2337/dc20-0170 Lithovius R, Harjutsalo V, Mutter S, Gordin D, Forsblom C, Groop P-H (2020) Resistant hypertension and risk of adverse events in individuals with type 1 diabetes: a Nationwide prospective study. Diabetes Care. 43(8):1885–1892. https://​doi.​org/​10.​2337/​dc20-0170
14.
go back to reference Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, New YorkCrossRef Therneau TM, Grambsch PM (2000) Modeling survival data: extending the cox model. Springer, New YorkCrossRef
41.
go back to reference Nicholson JK, Timbrell JA, Sadler PJ (1985) Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats. Mol Pharmacol 27(6):644–651PubMed Nicholson JK, Timbrell JA, Sadler PJ (1985) Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats. Mol Pharmacol 27(6):644–651PubMed
Metadata
Title
Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes
Authors
Stefan Mutter
Erkka Valo
Viljami Aittomäki
Kristian Nybo
Lassi Raivonen
Lena M. Thorn
Carol Forsblom
Niina Sandholm
Peter Würtz
Per-Henrik Groop
Publication date
01-01-2022
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 1/2022
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05584-3

Other articles of this Issue 1/2022

Diabetologia 1/2022 Go to the issue

Up Front

Up front

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.